Skip to main content

Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has a profound competitive advantage. To facilitate high yield production, Batavia Biosciences has developed STEP®, which enables the creation of stable, mammalian CHO cell lines with at least 10-fold more bioactive biosimilar product per CHO cell compared to commercial product and state-of-the-art scientific literature. In the rapidly growing market of biosimilars STEP® technology provides a substantial competitive advantage as it allows rapid completion of preclinical phases, significant reduction in R&D costs, and very high product yield in stable pharmaceutical grade CHO producer cell lines.

Read the full article on page 10/11:

BioProcess Featured Report – Biosimilars